Jiang C - Search Results

1

Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.

Hu JL, Wu JY, Xu S, Qian SY, Jiang C, Zheng GQ. Hu JL, et al. Among authors: jiang c. J Headache Pain. 2024 Oct 7;25(1):169. doi: 10.1186/s10194-024-01858-4. J Headache Pain. 2024. PMID: 39375581 Free PMC article.

2

Clinical safety evaluation of contrast agents based on real-world evidence.

Jiang C, Li J, Huang Y, Huang D, Lin J, Jiang X. Jiang C, et al. Among authors: jiang x. J Clin Pharm Ther. 2021 Dec;46(6):1600-1605. doi: 10.1111/jcpt.13485. Epub 2021 Jul 22. J Clin Pharm Ther. 2021. PMID: 34293194

3

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety.

Jiang C, Qian J, Jiang X, Zhang S, Zheng J, Wang H. Jiang C, et al. Among authors: jiang x. Pharmacol Res Perspect. 2024 Feb;12(1):e1161. doi: 10.1002/prp2.1161. Pharmacol Res Perspect. 2024. PMID: 38174838 Free PMC article.

4

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.

Qi Y, Li J, Lin S, Wu S, Chai K, Jiang X, Qian J, Jiang C. Qi Y, et al. Among authors: jiang c, jiang x. Sci Rep. 2024 May 18;14(1):11388. doi: 10.1038/s41598-024-62356-w. Sci Rep. 2024. PMID: 38762672 Free PMC article.

5

A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.

Jiang C, Zheng X, Li P, Qian J, Li Q. Jiang C, et al. Ther Adv Drug Saf. 2024 Jun 13;15:20420986241258049. doi: 10.1177/20420986241258049. eCollection 2024. Ther Adv Drug Saf. 2024. PMID: 38881538 Free PMC article.

6

Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database.

Wan X, Zhang S, Jiang C, Zhang H. Wan X, et al. Among authors: jiang c. Expert Opin Drug Saf. 2024 Jul 10:1-11. doi: 10.1080/14740338.2024.2371382. Online ahead of print. Expert Opin Drug Saf. 2024. PMID: 38898801

7

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database.

Qian J, Zhang S, Jiang C. Qian J, et al. Among authors: jiang c. BMC Cancer. 2024 Dec 3;24(1):1486. doi: 10.1186/s12885-024-13250-1. BMC Cancer. 2024. PMID: 39627756 Free PMC article.

8

Identification of high-risk patients for ADR induced by traditional Chinese medicine injection: a nested case-control study.

Jiang C, Shen J, Shou D, Wang N, Jing J, Zhang G, Gu J, Tian Y, Sun C, He J, Ma J, Wang X, Li G. Jiang C, et al. Sci Rep. 2019 Nov 13;9(1):16721. doi: 10.1038/s41598-019-53267-2. Sci Rep. 2019. PMID: 31723184 Free PMC article.

9

General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China.

Zheng ZQ, Jiang C, Yu RL, Zhou JQ, Wu ZJ, Luo JY. Zheng ZQ, et al. Among authors: jiang c. J Clin Pharm Ther. 2020 Oct;45(5):1087-1097. doi: 10.1111/jcpt.13174. Epub 2020 Jun 9. J Clin Pharm Ther. 2020. PMID: 32516456

10

The epidemiology and clinical features of post-exposure prophylaxis for rabies: A retrospective study of 9772 cases.

Jiang X, Li J, Pan J, Cheng L, Jiang C, Wang R. Jiang X, et al. Among authors: jiang c. One Health. 2024 Apr 29;18:100743. doi: 10.1016/j.onehlt.2024.100743. eCollection 2024 Jun. One Health. 2024. PMID: 38725962 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,601 results

Search Page

Filters